Kinetics of urea and β2-microglobulin during and after short hemodialysis treatments  by Leypoldt, John K. et al.
Kidney International, Vol. 66 (2004), pp. 1669–1676
Kinetics of urea and b2-microglobulin during and after short
hemodialysis treatments
JOHN K. LEYPOLDT, ALFRED K. CHEUNG, R. BARRY DEETER, ALEXANDER GOLDFARB-RUMYANTZEV,
TOM GREENE, THOMAS A. DEPNER, and JOHN KUSEK
VA Salt Lake City Health Care System, Salt Lake City, Utah; University of Utah, Salt Lake City, Utah; Cleveland Clinic Foundation,
Cleveland, Ohio; University of California, Davis, Sacramento, California; and National Institute of Diabetes and Digestive and
Kidney Diseases, National Institutes of Health, Bethesda, Maryland
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Background. Daily short hemodialysis (HD) is often pre-
scribed by simply doubling treatment frequency and halving
treatment time; however, the effect of this prescription ap-
proach on the equilibrated HD dose (urea eKt/V) and whole
body clearance for b 2-microglobulin has not been established.
Methods. We compared urea and b 2-microglobulin kinetics
during and 60 minutes after a short HD treatment and a con-
ventional HD treatment in a crossover study on 22 maintenance
HD patients: 16 male and 6 female, 61 ± 18 (mean ± standard
deviation) years of age. One patient in each treatment modal-
ity was excluded from certain analyses because of missing data.
Short and conventional HD treatments were essentially identi-
cal, except for treatment times, which were 116 ± 14 and 241 ±
27 minutes, respectively. Blood samples were collected at regu-
lar intervals during and after treatments, and additional blood
and dialysate samples were collected at 60 minutes of treatment
to evaluate dialyzer clearances.
Results. Plasma water urea clearances measured directly
across the dialyzer during short and conventional HD treat-
ments were not different (255 ± 23 mL/min and 255 ±
28 mL/min, respectively). The 60-minute postdialysis blood urea
nitrogen concentration rebounded more (P < 0.01) after short
HD than conventional HD (5.9 ± 3.1 vs. 4.0 ± 1.5 mg/dL,
respectively). Calculated urea eKt/V values using the
Daugirdas-Schneditz rate equation were not different from
those measured during conventional HD using the 60-minute
postdialysis concentration but significantly overestimated mea-
sured urea eKt/V values during short HD. Postdialysis rebound
of b 2-microglobulin concentrations was variable but simi-
lar after short and conventional HD treatments (0.1 ± 3.4
vs. 0.7 ± 1.8 mg/L, respectively). Whole body clearances of
b 2-microglobulin calculated from predialysis and immediate
(10-second) postdialysis serum concentrations during short and
conventional HD treatments were not different from each other
(42.9 ± 24.1 vs. 41.9 ± 22.4 mL/min, respectively).
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Conclusion. These observations show that the Daugirdas-
Schneditz rate equation is accurate in predicting urea eKt/V
during conventional, but not during short, HD. In contrast,
whole body clearances of b 2-microglobulin during short and
conventional HD treatments were similar. We conclude that
calculation of accurate estimates of urea eKt/V, but not clear-
ances of b 2-microglobulin, differ during short and conventional
HD treatments.
Daily short hemodialysis (HD) is increasingly used
worldwide in attempts to improve the outcome of chronic
hemodialysis patients; however, guidelines for treatment
prescriptions based on patient outcomes are virtually
nonexistent. The most common approach for dialysis pre-
scription during daily short HD is to double the number
of treatments per week from three to six, and simulta-
neously decrease the treatment time by half so that the
total treatment time per week remains constant [1–5]. Al-
ternative approaches using urea clearance times time di-
vided by urea distribution volume (Kt/V) have also been
attempted [6], including the possibility of applying flex-
ible schedules for patient convenience [7]. Finally, dose
measures such as the equivalent renal clearance [7] or
standard Kt/V for urea [8] have also been used for daily
short HD.
During conventional thrice-weekly HD therapy, dialy-
sis dose is most often assessed by measuring the predial-
ysis and postdialysis blood urea nitrogen concentrations
and calculating either the urea reduction ratio or Kt/V.
These parameters are not often corrected for postdialy-
sis urea rebound even though urea kinetics during HD
do not follow a model that is described by a single pool.
Failure to correct for the double-pool kinetics of urea
during routine therapy may not be critical for maintain-
ing quality assurance of dialysis delivery, but is required
for more rigorous assessments of the dose of HD [9], es-
pecially novel therapies that are not yet used routinely in
clinical practice, such as daily short HD. However, there
are few published data on the magnitude of urea rebound
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after short HD treatments; thus, the significance of urea
rebound in assessing a double-pool or equilibrated dose
of therapy during daily short HD is unclear.
The primary objective of the current study was to com-
pare intradialytic kinetics and the magnitude of postdial-
ysis rebound of urea and b 2-microglobulin for short HD
with those for conventional HD treatments. Further, the
applicability of rate equations [10–12] to predict equi-
librated Kt/V (eKt/V) from single-pool Kt/V (spKt/V)
values calculated from predialysis and immediate post-
dialysis blood urea nitrogen concentrations for both short
and conventional HD treatments was also assessed. Fi-
nally, the ability of previous formulas [13] for calculating
whole body b 2-microglobulin clearance from predialysis
and postdialysis serum b 2-microglobulin concentrations
for both short and conventional HD treatments was also
evaluated.
METHODS
Patients
Twenty-two chronic hemodialysis patients treated
three times per week by maintenance HD therapy were
recruited from two separate dialysis units within the Uni-
versity of Utah Dialysis Program. Patients were excluded
if they were medically unstable, had a hematocrit less
than 28% from the most recent monthly determination,
were hepatitis B–positive, hepatitis C–positive, or HIV-
positive, were prisoners, were pregnant women, were mi-
nors below 18 years of age, or were mentally disabled. All
study patients were informed of the purpose of the study
and gave written, informed consent. The protocol for this
study was approved by the Institutional Review Board at
the University of Utah.
The age of the patients was 61 ± 18 (standard devia-
tion) years. Sixteen of the patients were male and six were
female; 21 patients were Caucasian and one was Asian.
Fourteen patients had native fistulas, six had synthetic
grafts, and two used catheters for their vascular access.
Study design
This was a crossover study in which each patient was
studied on two separate occasions (one week apart) dur-
ing the patient’s routine HD treatment schedule. During
one study treatment, HD was performed according to the
patients’ routine prescription, with blood samples taken
during and for one hour after this treatment. During the
other study treatment, HD was performed for one half
of the prescribed treatment time, after which the dialy-
sis procedure was stopped for one hour while blood flow
was continued at a slow rate (120 mL/min) through the
extracorporeal circuit without dialysate flow. This latter
study treatment simulated a short HD treatment followed
by a one-hour postdialytic period. The remainder of the
prescribed HD treatment was then completed after this
one-hour pause period. The order of the study treatments
was not randomly assigned because of practical concerns
within the dialysis units. The first study treatment was
conventional HD for seven patients and short HD for
15 patients.
Clinical study procedures
During the study treatment using the routine prescrip-
tion, a blood sample (4 mL) was taken predialysis from
the vascular access and at 30, 60, 120, 180 minutes from
the arterial blood tubing of the extracorporeal dialysis
circuit. At the end of the treatment, the blood flow rate
was decreased to 120 mL/min and blood samples were
taken after 10 seconds, 2, 10, 30, and 60 minutes. After
60 minutes of treatment, additional samples were taken
from the venous blood tubing and the dialysate outflow
to permit direct evaluation of dialyzer clearances. This
protocol permitted evaluation of solute kinetics during
and after a conventional HD treatment.
During the other study treatment, a blood sample
(4 mL) was taken predialysis from the vascular access and
at 30, 60, and 90 minutes from the arterial blood tubing.
At the midpoint of the treatment (i.e., half of the usual
treatment time), the ultrafiltration rate was adjusted to
the minimum setting and the dialysate flow was stopped.
The blood flow rate was decreased to 120 mL/min for one
hour, and blood samples were taken after 10 seconds, 2,
10, 30, and 60 minutes. After this one-hour pause period,
HD was restarted and continued to complete the usual
treatment. Sixty minutes into this alternative treatment,
additional samples were taken from the venous blood
tubing and the dialysate outflow to permit the direct eval-
uation of dialyzer clearances. This protocol permitted the
study of solute kinetics and postdialysis solute rebound
for one hour after a short treatment without significantly
interfering with the patient’s scheduled HD treatment.
After the conventional HD treatment, a predialysis
blood sample was taken at the next scheduled HD treat-
ment (two days later) to evaluate the interdialytic urea
generation rate. High flux dialyzers (Optiflux F160NR
in 10 patients, and Optiflux F200NR in 12 patients; Fre-
senius North America, Ogden, UT, USA) were used at
routinely prescribed blood, dialysate, and ultrafiltration
flow rates. The actual blood flow rate was measured us-
ing the HD01 monitor (Transonic Systems, Ithaca, NY,
USA) at 60 minutes during each study treatment.
Analytical assays
All blood and dialysate samples were collected in tubes
without additional anticoagulant and allowed to stand
at room temperature for 30 to 60 minutes. The sam-
ples were then centrifuged and the serum collected and
stored at −70◦C until they were assayed. All samples
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were assayed for the concentrations of urea and b 2-
microglobulin. Urea nitrogen was measured using an
automated analyzer (Beckman CX7; Beckman Coulter,
Fullerton, CA, USA), and serum concentrations of b 2-
microglobulin were measured using a radioimmunoassay
(Immunos, Albany, CA, USA). Dialysate concentrations
of b 2-microglobulin were frequently below 1 mg/L, and
were considered to be too low for accurate determi-
nations of b 2-microglobulin clearance (see below). Al-
though the measured urea nitrogen concentration is that
in serum, by convention, it will be referred to as the blood
urea nitrogen (BUN) concentration. To assess plasma
volume depletion during the study treatments, predialy-
sis and immediate (10-second) postdialysis samples were
also assayed for serum albumin concentrations using an
automated analyzer (Beckman Coulter).
Data analysis
Blood-side and dialysate-side clearances for urea dur-
ing conventional and short HD treatments were calcu-
lated using standard formulas and compared using paired
Student t test. Blood-side blood water clearances were
corrected by assuming that 89.4% of blood flow consists
of blood water [14]. Postdialysis rebound was calculated
both in concentration units and as a fraction of the imme-
diate postdialysis serum concentration (10 seconds after
slowing the blood flow rate to 120 mL/min); the extent
of postdialysis rebound for short and conventional HD
treatments was compared using repeated measures anal-
ysis of variance (ANOVA).
Single-pool urea Kt/V (spKt/V) values were calculated
from the immediate (10-second) postdialysis concentra-
tion for both short and conventional HD treatments using
the second generation Daugirdas formula [15] or
spKt/V = −ln(R − 0.008 × T) + (4 − 3.5 × R)
× UF/BW (1)
where R denotes the ratio of the postdialysis to predialy-
sis BUN concentration, T is treatment time in hours, UF
is the volume of fluid removed during treatment in L, and
BW is the postdialysis body weight in kg.
Equilibrated Kt/V (eKt/V) values were calculated
using the rate equations described by Daugirdas and
Schneditz [10]
eKt/V = spKt/V − 0.6 × spKt/V/T + 0.03 (2)
and that recently derived from observations during the
Hemodialysis (HEMO) Study [11, 12]
eKt/V = spKt/V − 0.39 × spKt/V/T (3)
An alternative to these rate equations is that described
by Tattersall et al [16], or
eKt/V = spKt/V × (t/(t + 35)) (4)
(here, t indicates treatment time in minutes), and this
equation was also used to calculate eKt/V. Equilibrated
Kt/V values were also calculated from equation 1 using
the 60-minute postdialysis concentrations (after correc-
tion for urea generation [17]); these values are referred to
as the measured eKt/V values. The urea distribution vol-
ume was calculated from measured eKt/V, directly mea-
sured dialyzer clearance of urea, and treatment time. All
calculated eKt/V values were compared with those mea-
sured using a paired Student t test.
Whole body clearance of b 2-microglobulin was cal-
culated using the formula described previously [13], as-
suming the distribution volume for b 2-microglobulin was
one third of that for urea. Because the dialysate con-
centrations of b 2-microglobulin were low, and because
b 2-microglobulin can adsorb to the membrane, the evalu-
ation of its clearance directly across the dialyzer was only
calculated using the blood-side, and not the dialysate-
side, measurements. When evaluating this clearance for
b 2-microglobulin, the arterial plasma flow rate was calcu-
lated as the measured blood flow rate times one minus the
hematocrit. The venous plasma flow rate was calculated
as the arterial plasma flow rate minus the ultrafiltration
rate. A standard formula for calculating blood-side clear-
ance directly across the dialyzer from arterial and venous
serum b 2-microglobulin concentrations and plasma flow
rates was used.
Fractional plasma volume depletion (PVD) as the re-
sult of HD treatment was calculated assuming no loss of
albumin from the plasma space during the treatment as
PVD = (PVi − PVf)/PVi = (Af − Ai)/Af (5)
where PV and A denote plasma volume and serum al-
bumin concentration, and the subscript i and f denote
predialysis and immediate (10-second) postdialysis val-
ues, respectively.
All empirical and calculated values are reported as
mean ± standard deviation. All regression coefficients
are reported as mean ± standard error.
RESULTS
Kinetics of urea
Table 1 shows treatment parameters for all 22 patients
studied. By design, no differences were observed dur-
ing short and conventional HD except treatment time
and fluid removed because only half of the prescribed
fluid loss was removed during the short HD treatment.
Urea transfer characteristics for both Optiflux F160NR
and F200NR dialyzers measured from cross dialyzer mea-
surements are also reported in Table 1. No differences in
dialyzer urea transfer characteristics were apparent dur-
ing short and conventional HD treatments.
Figure 1 shows the time-dependent changes in BUN
concentrations during and 60 minutes after both short
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Table 1. Treatment and dialyzer clearance characteristics during
short and conventional HD
Short Conventional
Characteristic N HD HD
Treatment time minutes 22 116 ±14 241 ± 27
Blood flow rate mL/min 22 338 ± 50 338 ± 51
Dialysate flow rate mL/min 22 540 ± 62 540 ± 60
Fluid removed L 22 1.4 ± 0.7 3.2 ± 1.1
Postdialysis body weight kg 22 80.2 ± 19.7 80.4 ± 19.7
Plasma water dialyzer 22 255 ± 23 255 ± 28
clearance of urea mL/min
Urea KoA for 10 826 ± 173 838 ± 211
Optiflux F160A dialyzers mL/min
Urea KoA for Optiflux 12 953 ± 200 1000 ± 189
F200A dialyzers mL/min
Values are expressed as mean ± standard deviation.
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Fig. 1. Time dependence of blood urea nitrogen (BUN) concentra-
tions during and 60 minutes after short (triangles, dashed lines) and
conventional (squares, solid lines) hemodialysis (HD) treatments. The
final times of short and conventional HD treatments were assumed to
be 120 and 240 minutes, respectively. Mean values from 21 treatment
sessions for both short and conventional HD are shown.
and conventional HD treatments. The decrease in BUN
concentrations during both treatments was similar; how-
ever, the magnitude of the rebound in BUN, when mea-
sured in absolute concentrations was greater (P < 0.01)
after short HD than after conventional HD treatments
(5.9 ± 3.1 vs. 4.0 ± 1.5 mg/dL, respectively, see Fig. 2).
When expressed as a percentage of the immediate (10-
second) postdialysis values, however, the rebound after
60 minutes was actually lower for short (21.7 ± 7.6%)
than for conventional (27.5 ± 8.5%) HD treatments.
Table 2 compares estimates of urea kinetic parame-
ters evaluated during short and conventional HD treat-
ments. Calculated values of spKt/V for short HD were
approximately one half of those for conventional HD
treatments. Calculated values of eKt/V estimated using
the Daugirdas-Schneditz rate equation (0.60 ± 0.07 and
1.38 ± 0.14, respectively) were approximately 8% less
(P < 0.001) than those measured during short HD treat-
ments (0.66 ± 0.08), but were not different from those
directly measured (1.37 ± 0.13) during conventional HD
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Fig. 2. Postdialysis rebound of blood urea nitrogen (BUN) concentra-
tions calculated as the increase in concentration (in absolute magnitude)
from its value 10 seconds after completion of conventional (squares,
solid lines) and short (triangles, dashed lines) hemodialysis (HD) treat-
ments. BUN concentrations were not corrected for interdialytic gener-
ation of urea. Mean values from 21 treatment sessions for both conven-
tional and short HD are shown.
Table 2. Urea kinetic parameters during short and conventional HD
treatments
Urea kinetic parameter Short HD Conventional HD
spKt/V 0.84 ± 0.11 1.59 ± 0.17
Measured eKt/V 0.66 ± 0.08 1.37 ± 0.13
Daugirdas-Schneditz eKt/V 0.60 ± 0.07a 1.38 ± 0.14
HEMO Study eKt/V 0.67 ± 0.08 1.43 ± 0.15a
Tattersall et al eKt/V 0.64 ± 0.08 1.38 ± 0.15
All values are based on N = 21, and are expressed as mean ± standard
deviation.
aDifferent from measured eKt/V value (P < 0.001).
treatments. In contrast, calculated values of eKt/V using
the HEMO Study rate equation (0.67 ± 0.08 and 1.43 ±
0.15, respectively) were not significantly different from
those directly measured during short HD treatments, but
was approximately 5% greater (P < 0.001) than those
directly measured during conventional HD treatments.
Also shown in Table 2 are calculated values of eKt/V
predicted using the equation suggested by Tattersall
et al [16]. The predicted eKt/V values using this equation
(0.64 ± 0.08 and 1.38 ± 0.15, respectively) were not dif-
ferent from those directly measured during both short
(P = 0.16) and conventional (P = 0.20) HD treatments.
The differences between measured and calculated
eKt/V values are plotted versus treatment time in
Figure 3. The slope of the regression of these data points
was negative when predicting eKt/V using the Daugirdas-
Schneditz rate equation (P < 0.001, Fig. 3A) and the
HEMO Study rate equation (P = 0.01, Fig. 3B). The slope
was also negative in magnitude when predicting using the
Tattersall et al equation, but this value was not statisti-
cally different from zero (P = 0.13).
Multiple linear regression analysis showed that both
the rate of HD treatment (spKt/V/T or spK/V) and the
dose (spKt/V) are significant predictors of the measured
eKt/V. Thus, based on the current data, valid estimates
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Fig. 3. The difference between the equilibrated Kt/V (eKt/V) directly
measured and that calculated by four separate rate equations plotted
versus treatment time. Data from 42 treatment sessions are shown; those
from patients treated with catheters are shown as open symbols. (A)
Comparison with that calculated by the Daugirdas-Schneditz rate equa-
tion: the best fit linear regression equation was Y = −4.83 (±1.30) ×
10−4 X + 0.108 (±0.025), P < 0.001. (B) Comparison with that calcu-
lated by the HEMO Study rate equation: the best fit linear regression
equation was Y = −3.61 (±1.40) × 10−4 X + 0.027 (±0.027), P = 0.01.
(C) Comparison with that calculated by the Tattersal et al equation: the
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Fig. 4. Direct comparison of eKt/V calculated using the equation de-
rived in this study, equation 6, with measured values of eKt/V (N = 21).
of eKt/V depend on both the rate and dose of treatment;
the equation that best predicts eKt/V from these factors
was the following:
eKt/V = 0.915 × spKt/V − 0.485
× spKt/V/T + 0.106 (6)
The difference between measured eKt/V values and
those predicted using equation 6 are shown in Figure 3D
versus treatment time for both short and conventional
HD treatments combined. The slope of this equation is
not significantly different from zero (P = 0.87). Figure 4
plots values of eKt/V predicted using equation 6 ver-
sus those measured. The high precision of the predicted
eKt/V values in equation 6 is largely because it is a three-
parameter equation, whereas equations 2 to 4 only con-
tain one or two adjustable parameters.
Kinetics of b2-microglobulin
Figure 5 shows the time dependence of serum b 2-
microglobulin concentrations during and 60 minutes
after both short and conventional HD treatments. The
decrease in serum b 2-microglobulin concentration dur-
ing both treatments was similar during the first two
hours of treatment. Postdialysis rebound for serum b 2-
microglobulin concentration 60 minutes after treatment
was variable; the average magnitude of the rebound was
less then 1.0 mg/L for both short and conventional HD
treatments (0.1 ± 3.4 vs. 0.7 ± 1.8 mg/L, respectively).
When expressed as percentages, postdialysis rebound of
serum b 2-microglobulin concentrations was 3.5 ± 23.0%
best fit linear regression equation was Y = −2.04 (±1.33) × 10−4 X +
0.035 (±0.025), P = 0.13. (D) Comparison with that calculated by the
rate equation derived from the data in this study (equation 5): the best
fit linear regression equation was Y = −0.23 (±1.24) × 10−4 X – 0.004
(±0.024), P = 0.85.
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Fig. 5. Time dependence of b2-microglobulin (Beta-2-M) concentra-
tions during and 60 minutes after short (triangles, dashed lines) and
conventional (squares, solid lines) hemodialysis (HD) treatments. The
final times of short and conventional HD treatments were assumed as
120 and 240 minutes, respectively. Mean values from 21 treatment ses-
sions for both short and conventional HD are shown.
Table 3. Clearances of b 2-microglobulin during short and
conventional HD treatments calculated from predialysis and
postdialysis concentrations (whole body) or directly across the
dialyzer
b 2-microglobulin clearance Short HD Conventional HD
Whole body 42.9 ± 24.1 41.9 ± 22.4
Cross-dialyzer 24.8 ± 19.1 19.4 ± 21.0
All values are expressed in mL/min, based on N = 21, and reported as mean
± standard deviation.
and 6.5 ± 13.6% for short and conventional HD treat-
ments, respectively.
Calculated values of whole body b 2-microglobulin
clearance from predialysis and postdialysis (10-second)
concentrations [11, 13] and those measured directly
across the dialyzer are shown in Table 3. Whole body b 2-
microglobulin clearances yielded values of 42.9 ± 24.1
and 41.9 ± 22.4 mL/min for short HD and conventional
HD treatments, respectively. When both short and con-
ventional HD treatments were combined for Optiflux
F160NR and Optiflux F200NR dialyzers, the calculated
whole body b 2-microglobulin clearances were 42.9 ± 24.6
and 41.9 ± 21.9 mL/min, respectively. None of the dif-
ferences in any calculated whole body b 2-microglobulin
clearances were statistically significant. Calculated clear-
ances of b 2-microglobulin across the dialyzer were ap-
proximately half of those calculated from predialysis and
postdialysis concentrations, but were similar for both
short and conventional HD treatments (Table 3).
Predialysis and immediate (10-second) postdialysis
serum albumin concentrations were 3.5 ± 0.3 and 3.4 ±
0.4 g/dL for short HD and 3.4 ± 0.4 and 3.5 ± 0.5 g/dL
for conventional HD treatments. Calculated plasma vol-
ume depletion was −2.2% ± 7.1% for short HD and
1.9% ± 8.7% for conventional HD treatments, respec-
tively. These data suggest that plasma volume depletion
was small and quite variable in these studies.
DISCUSSION
A more accurate measure of the true dose of hemodial-
ysis than spKt/V is the parameter urea eKt/V, which can
be most accurately determined using the equilibrated
BUN concentration obtained at 60 minutes’ postdialysis
[9]. Assessment of conventional hemodialysis dose using
the concept of urea eKt/V can be performed using an
immediate (10- or 20-second) postdialysis blood sample
only if it is corrected for postdialysis rebound of urea. Sev-
eral equations have been previously proposed to correct
for postdialysis urea rebound [10–12, 16, 18, 19], and some
of these formulas have been shown to be approximately
equivalent to each other during conventional HD treat-
ments [20]. The formulas by both Daugirdas-Schneditz
and Tattersall et al have been shown to accurately cor-
rect for postdialysis rebound of urea during conventional
HD treatments [17, 19, 21, 22]; however, the adaptability
of these equations to short HD treatments has not been
studied extensively.
The results from the current study show that neither the
Daugirdas-Schneditz nor the HEMO Study rate equation
is accurate in predicting postdialysis urea rebound after
both short and conventional HD treatments. As in several
previous studies [17, 19, 21, 22], the current observations
show that the Daugirdas-Schneditz rate equation is accu-
rate in predicting postdialysis urea rebound after conven-
tional HD treatments. The results from this study show,
however, that this equation is not accurate in predict-
ing postdialysis urea rebound after short HD treatments.
Paradoxically, the current observations suggest that the
HEMO Study rate equation cannot be used to correct for
postdialysis urea rebound during conventional HD treat-
ments. One possible reason for this discrepancy is that
the immediate postdialysis sample in the current study
was collected after 10 seconds (using a blood flow rate of
120 mL/min) instead of the 20 seconds preferred in the
HEMO Study (using a blood flow rate of approximately
80 mL/min). We chose to sample postdialysis blood as
proposed by Kapoian et al [23] because of concerns of
potential thrombosis in the extracorporeal circuit during
our unique study protocol. It is possible that sampling
blood during this shorter time period after ending the HD
treatments more accurately assessed postdialysis urea re-
bound due to access recirculation, uncontaminated by
that caused by cardiopulmonary recirculation.
Our results further suggest that the formula proposed
by Tattersall et al [16] may be more useful for predicting
postdialysis urea rebound during short HD treatments
because its predictions of urea eKt/V were not statistically
different from those values directly measured (Fig. 3C).
It should be noted, however, that the accuracy of the
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Tattersall et al equation in predicting the measured eKt/V
was not considerably greater than those using the other
equations. Further studies using large numbers of HD pa-
tients will be necessary to determine the accuracy of the
Tattersall et al equation for predicting postdialysis urea
rebound during both short and conventional HD treat-
ments. The prediction of postdialysis urea rebound and
eKt/V is more precise if equation 6 is used instead.
It should be noted that two patients in this study
had a catheter as their vascular access. The kinetics of
postdialysis urea rebound for these patients may be differ-
ent from those with an arteriovenous vascular access [10].
In this study we combined all patients for analysis because
it was not obvious that the patients with central accesses
were substantially different from the other patients (see
Fig. 3). Furthermore, reanalysis of these data excluding
those patients did not alter the conclusions from these
data analyses.
Based on the results summarized in Table 2, we can
estimate the sum total of urea eKt/V delivered per week
during short and conventional HD as 3.96 (6 × 0.66/treat-
ment) and 4.11 (3 × 1.37/treatment), respectively, when
short HD treatments are prescribed by doubling treat-
ment frequency and halving treatment time per session.
This calculation indicates a small decrease (approxi-
mately 4%) in weekly eKt/V per week during daily short
HD compared with that for conventional HD therapy.
Using standard urea Kt/V as described by Gotch [24, 25]
as the dose measure, however, the hemodialysis dose dur-
ing daily short HD will considerably exceed that during
conventional HD. Whether the adequate treatment dose
is better evaluated using the weekly standard urea Kt/V
than weekly eKt/V will require data on clinical outcomes
using these parameters as guides of therapy.
In contrast to urea, clearances of b 2-microglobulin (cal-
culated either using predialysis and postdialysis serum
concentrations or directly across the dialyzer) during
short and conventional HD treatments were indistin-
guishable. Such agreement may be partly due to the lack
of significant postdialysis rebound of b 2-microglobulin in
this study compared with that previously reported [26].
The magnitude of postdialysis rebound reported in the
current study was closer to that reported in preliminary
data from the HEMO Study of approximately 4% [ab-
stract; Leypoldt et al, J Am Soc Nephrol 9:299A, 1998].
The lack of postdialysis rebound of b 2-microglobulin
in this study may have been due to substantial plasma
volume depletion during these treatments; however, the
method used for calculating this parameter from changes
in serum albumin concentrations may not have been accu-
rate enough to demonstrate this. The current results sug-
gest that single compartment models of b 2-microglobulin
kinetics may have only limited usefulness for evaluat-
ing removal of middle molecules during daily short HD
therapy.
CONCLUSION
The results from this study demonstrate that calcu-
lation of accurate estimates of urea eKt/V, but not of
clearances of b 2-microglobulin, differ during short and
conventional HD treatments. It is important to note that
these studies were performed during only a single isolated
short treatment, and may not apply to patients treated
regularly using short HD treatments. Further studies in
the latter patients are necessary to validate these findings.
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